<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title-group><journal-title>BMC Medical Genetics</journal-title></journal-title-group><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-11-7</article-id><article-id pub-id-type="pmid">20078883</article-id><article-id pub-id-type="doi">10.1186/1471-2350-11-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research article</subject></subj-group></article-categories><title-group><article-title>Association of <italic>MMP - 12 </italic>polymorphisms with severe and very severe COPD: A case control study of <italic>MMP</italic>s - <italic>1, 9 and 12 </italic>in a European population</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Haq</surname><given-names>Imran</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>mrxiuh@nottingham.ac.uk</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Chappell</surname><given-names>Sally</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sally.chappell@nottingham.ac.uk</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Johnson</surname><given-names>Simon R</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>simon.johnson@nottingham.ac.uk</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Lotya</surname><given-names>Juzer</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>juzer.lotya@ucd.ie</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Daly</surname><given-names>Leslie</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>leslie.daly@ucd.ie</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Morgan</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Kevin.morgan@nottingham.ac.uk</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Guetta-Baranes</surname><given-names>Tamar</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>tamar.guetta-baranes@nottingham.ac.uk</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Roca</surname><given-names>Josep</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>JROCA@clinic.ub.es</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Rabinovich</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I8">8</xref><email>roberto.rabinovich@ed.ac.uk</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Millar</surname><given-names>Ann B</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>Ann.Millar@bristol.ac.uk</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Donnelly</surname><given-names>Seamas C</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>seamas.donnelly@ucd.ie</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Keatings</surname><given-names>Vera</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>Vera.Keatings@nwhb.ie</email></contrib><contrib contrib-type="author" id="A13"><name><surname>MacNee</surname><given-names>William</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>wmacnee@ed.ac.uk</email></contrib><contrib contrib-type="author" id="A14"><name><surname>Stolk</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>j.stolk.long@lumc.nl</email></contrib><contrib contrib-type="author" id="A15"><name><surname>Hiemstra</surname><given-names>Pieter S</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>phiemstra@lumc.nl</email></contrib><contrib contrib-type="author" id="A16"><name><surname>Miniati</surname><given-names>Massimo</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>miniati@ifc.cnr.it</email></contrib><contrib contrib-type="author" id="A17"><name><surname>Monti</surname><given-names>Simonetta</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>monti@ifc.cnr.it</email></contrib><contrib contrib-type="author" id="A18"><name><surname>O'Connor</surname><given-names>Clare M</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>clare.oconnor@ucd.ie</email></contrib><contrib contrib-type="author" id="A19"><name><surname>Kalsheker</surname><given-names>Noor</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>noor.kalsheker@nottingham.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>School of Molecular Medical Sciences, Institute of Genetics, Queen's Medical Centre, University of Nottingham, UK</aff><aff id="I2"><label>2</label>Therapeutics and Molecular Medicine, Queen's Medical Centre, University of Nottingham, UK</aff><aff id="I3"><label>3</label>UCD School of Public Health and Population Science, University College Dublin, Belfield, Dublin, Ireland</aff><aff id="I4"><label>4</label>Pulmonary Dept, CIBERES, Hospital Clinic, Hospital Cl&#x000ed;nico y Provincial de Barcelona, Villarroel, Barcelona, Spain</aff><aff id="I5"><label>5</label>Lung Research Group, Dept of Clinical Science at North Bristol, Southmead Hospital, University of Bristol, Westbury on Trym, Bristol, UK</aff><aff id="I6"><label>6</label>UCD School of Medicine and Medical Science, UCD Conway Institute, University College Dublin, Ireland</aff><aff id="I7"><label>7</label>Letterkenny General Hospital, Letterkenny, Donegal, Ireland</aff><aff id="I8"><label>8</label>Respiratory Medicine, ELEGI Colt Laboratories, Wilkie Building, University of Edinburgh, Edinburgh, UK</aff><aff id="I9"><label>9</label>Dept of Pulmonology (C3-P), Leiden University Medical Center, Leiden, The Netherlands</aff><aff id="I10"><label>10</label>Department of Medical and Surgical Critical Care, University of Florence, Italy</aff><aff id="I11"><label>11</label>CNR Institute of Clinical Physiology, Pisa, Italy</aff><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>15</day><month>1</month><year>2010</year></pub-date><volume>11</volume><fpage>7</fpage><lpage>7</lpage><history><date date-type="received"><day>5</day><month>10</month><year>2009</year></date><date date-type="accepted"><day>15</day><month>1</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2010 Haq et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Haq et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2350/11/7"/><abstract><sec><title>Background</title><p>Genetic factors play a role in chronic obstructive pulmonary disease (COPD) but are poorly understood. A number of candidate genes have been proposed on the basis of the pathogenesis of COPD. These include the <italic>matrix metalloproteinase </italic>(<italic>MMP</italic>) genes which play a role in tissue remodelling and fit in with the protease - antiprotease imbalance theory for the cause of COPD. Previous genetic studies of <italic>MMP</italic>s in COPD have had inadequate coverage of the genes, and have reported conflicting associations of both single nucleotide polymorphisms (SNPs) and SNP haplotypes, plausibly due to under-powered studies.</p></sec><sec><title>Methods</title><p>To address these issues we genotyped 26 SNPs, providing comprehensive coverage of reported SNP variation, in <italic>MMP</italic>s- 1, 9 and 12 from 977 COPD patients and 876 non-diseased smokers of European descent and evaluated their association with disease singly and in haplotype combinations. We used logistic regression to adjust for age, gender, centre and smoking history.</p></sec><sec><title>Results</title><p>Haplotypes of two SNPs in <italic>MMP</italic>-12 (rs652438 and rs2276109), showed an association with severe/very severe disease, corresponding to GOLD Stages III and IV.</p></sec><sec><title>Conclusions</title><p>Those with the common A-A haplotype for these two SNPs were at greater risk of developing severe/very severe disease (p = 0.0039) while possession of the minor G variants at either SNP locus had a protective effect (adjusted odds ratio of 0.76; 95% CI 0.61 - 0.94). The A-A haplotype was also associated with significantly lower predicted FEV<sub>1 </sub>(42.62% versus 44.79%; p = 0.0129). This implicates haplotypes of <italic>MMP-12 </italic>as modifiers of disease severity.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality worldwide. The World Health Organisation's Global Burden of Disease and Risk Factors project estimates that in 2001, COPD was the fifth leading cause of death in high-income countries and the sixth leading cause of death in countries of low and middle income [<xref ref-type="bibr" rid="B1">1</xref>]. Cigarette smoking is the main aetiological risk factor in disease development. However, only about 10 - 20% of smokers develop clinically significant COPD though this may be an under-estimate [<xref ref-type="bibr" rid="B2">2</xref>]. Furthermore, there is variability between smokers who have similar levels of smoke exposure, with many developing milder forms of the disease [<xref ref-type="bibr" rid="B3">3</xref>]. These observations suggest that underlying genetic factors contribute to either disease susceptibility or protection.</p><p>A widely accepted hypothesis of COPD causation is an imbalance of proteolytic enzymes and their inhibitors based on the observation that severe alpha<sub>1</sub>-antitrypsin deficiency predisposes cigarette smokers to the development of pulmonary emphysema in early adult life. This is thought to be due to uninhibited neutrophil elastase (NE) activity degrading elastin, a major component of lung connective tissue [<xref ref-type="bibr" rid="B4">4</xref>]. There are a number of other proteolytic enzymes also capable of degrading elastin, most particularly the <italic>matrix metalloproteinase</italic>s (<italic>MMP</italic>s), a family of potent proteinases that degrade all the major protein components of the extra-cellular matrix (ECM).</p><p><italic>MMP</italic>s play a key role in tissue remodelling and repair and there is significant evidence that members of the <italic>MMP </italic>family may also play an important role in COPD pathology. Transgenic mice over-expressing <italic>MMP-1 </italic>develop emphysema [<xref ref-type="bibr" rid="B5">5</xref>], whilst <italic>MMP-12 </italic>knockout mice are protected from emphysema despite prolonged cigarette smoke exposure[<xref ref-type="bibr" rid="B6">6</xref>], implicating <italic>MMP-12 </italic>as a compelling emphysema determinant in this model. In COPD patients a range of studies implicate <italic>MMP</italic>s in the pathogenesis of the disease [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. A number of studies have reported associations of genetic variants in <italic>MMPs-1, 9 and 12 </italic>with COPD or related phenotypes. <italic>MMP-1 </italic>and <italic>MMP-12 </italic>are located in close proximity on chromosome 11 and <italic>MMP-9 </italic>is located on chromosome 20. Reported associations of these genes with COPD include associations of haplotypes of <italic>MMP</italic>s- <italic>1 and 12 </italic>with rate of decline in lung function [<xref ref-type="bibr" rid="B13">13</xref>] in Caucasians and association of an <italic>MMP-9 </italic>promoter polymorphism with emphysema in a Japanese population [<xref ref-type="bibr" rid="B14">14</xref>]. However, there are conflicting data on the potential involvement of <italic>MMP </italic>variation in COPD. This likely reflects a number of issues relating to false positives in case- control studies or a lack of power due to relatively small sample size and the limited number of single nucleotide polymorphisms (SNPs) investigated, <italic>MMP 1, 9 and 12 </italic>studies are summarised in table <xref ref-type="table" rid="T1">1</xref>. Other issues that contribute to lack of reproducibility include variation in the definition of cases and controls, improper matching of cases and controls and ethnic differences [<xref ref-type="bibr" rid="B15">15</xref>]. The results therefore need to be interpreted with caution.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Previous association studies performed in COPD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Author<break/>(Year)</th><th align="left">Case</th><th align="left">Control</th><th align="left">Population</th><th align="left">Gene (Polymorphism)</th><th align="left">rs number</th><th align="left">Findings</th></tr></thead><tbody><tr><td align="left">Minesmatu <italic>et al </italic>(2001) [<xref ref-type="bibr" rid="B14">14</xref>]</td><td align="left">45 COPD, emphysema on CT-Scan</td><td align="left">65 Smokers,<break/>No emphysema on CT-Scan</td><td align="left">Japanese</td><td align="left">MMP9 (-1562C/T)</td><td align="left">rs3918242</td><td align="left">T allele with Emphysema<break/>DLco/VA lower and emphysemous changes distinct with C/T and T/T</td></tr><tr><td colspan="7"><hr/></td></tr><tr><td align="left">Joos <italic>et al </italic>(2002) [<xref ref-type="bibr" rid="B13">13</xref>]</td><td align="left">284 fast rate of lung function decline</td><td align="left">306 slow rate of lung function decline</td><td align="left">Caucasian (USA)</td><td align="left">MMP1 (-1607G/GG)<break/>MMP9 (CA Repeat)<break/>MMP9 (-1562C/T)<break/>MMP12 (-82A/G)<break/>MMP12 (357Asn/Ser)</td><td align="left">rs1799750<break/>N/A<break/>rs3918242<break/>rs2276109<break/>rs652438</td><td align="left">-1607GG associated with fast rate of decline of lung function<break/>Haplotypes of 357Asn/Ser and -1607G/GG associated with rate of decline of lung function</td></tr><tr><td colspan="7"><hr/></td></tr><tr><td align="left">Zhou <italic>et al </italic>2004) [<xref ref-type="bibr" rid="B33">33</xref>]</td><td align="left">100 COPD</td><td align="left">98 healthy smokers</td><td align="left">Han (South China)</td><td align="left">MMP9 (-1562C/T)</td><td align="left">rs3918242</td><td align="left">C/T and T allele frequencies significantly higher in COPD patients</td></tr><tr><td colspan="7"><hr/></td></tr><tr><td align="left">Zhang <italic>et al</italic><break/>(2005) [<xref ref-type="bibr" rid="B30">30</xref>]</td><td align="left">147 COPD</td><td align="left">120 healthy smokers</td><td align="left">Han (North China)</td><td align="left">MMP1 (-1607G/GG)<break/>MMP9 (-1562C/T)<break/>MMP12 (-82A/G)<break/>MMP12 (357Asn/Ser)</td><td align="left">rs1799750<break/>rs3918242<break/>rs2276109<break/>rs652438</td><td align="left">357 Asn/Asn is a risk factor for COPD</td></tr><tr><td colspan="7"><hr/></td></tr><tr><td align="left">Ito <italic>et al </italic>2005) [<xref ref-type="bibr" rid="B34">34</xref>]</td><td align="left">84 COPD</td><td align="left">85 healthy smokers</td><td align="left">Japanese</td><td align="left">MMP9 (-1562C/T)</td><td align="left">rs3918242</td><td align="left">T allele associated with upper lung dominant emphysema</td></tr><tr><td colspan="7"><hr/></td></tr><tr><td align="left">Hersh <italic>et al </italic>2006) [<xref ref-type="bibr" rid="B35">35</xref>]</td><td align="left">304 COPD<break/>127 families early onset<break/>COPD</td><td align="left">441 healthy smokers<break/>N/A</td><td align="left">Caucasian<break/>(USA)</td><td align="left">MMP1 (-1607G/GG)<break/>MMP9 (CA Repeat)</td><td align="left">rs1799750<break/>N/A</td><td align="left">No Association found</td></tr><tr><td colspan="7"><hr/></td></tr><tr><td align="left">Tesfaigzi et al<break/>(2006) [<xref ref-type="bibr" rid="B25">25</xref>]</td><td align="left">385 male COPD with &#x0003e; 20 Pack Years</td><td align="left">N/A</td><td align="left">Caucasian<break/>(USA)</td><td align="left">MMP1 (-1607G/GG)<break/>MMP9 (279 R/Q)<break/>MMP9 (-1562C/T)<break/>MMP9 (CA Repeat)</td><td align="left">rs1799750<break/>rs17576<break/>rs3918242<break/>N/A</td><td align="left">Homozygous 279Arg associated with 3&#x000d7; risk for COPD.<break/>Haplotype containing 279Arg and CA associated with COPD risk.</td></tr><tr><td colspan="7"><hr/></td></tr><tr><td align="left">Schirmer <italic>et al </italic>(2009) [<xref ref-type="bibr" rid="B36">36</xref>]</td><td align="left">111 COPD</td><td align="left">101 Non smoking controls</td><td align="left">Caucasian<break/>(Brazil)</td><td align="left">MMP9 (-1562C/T)<break/>MMP12 (-82A/G)</td><td align="left">rs3918242<break/>rs2276109</td><td align="left">No Association found</td></tr></tbody></table></table-wrap><p>To address the major issues, a European cohort of 977 Caucasian COPD patients and 876 non-diseased smoking controls with complete genotyping information was used to evaluate the relationship of 26 SNPs within <italic>MMP</italic>s- <italic>1, 9 </italic>and <italic>12 </italic>with COPD and to investigate associations with GOLD -defined severity phenotypes. These tagging SNPs provide coverage of most of the variation within the <italic>MMP </italic>genes.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>COPD and non-diseased smoking control subjects were recruited from six European centres. Only white Caucasians were recruited. Study approval was obtained from appropriate local committees to each recruitment centre. Informed consent was obtained from all subjects. The resource of COPD patients and non-diseased smoking controls has been described previously [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B19">19</xref>] and is one of the largest reported to date. The number of subjects recruited from each centre was as follows. Barcelona (Spain): 70 controls and 138 cases; Bristol (UK): 152 controls and 129 cases; Dublin (Ireland): 195 controls and 196 cases; Edinburgh (UK): 81 controls and 168 cases; Leiden (the Netherlands): 216 controls and 188 cases; and Pisa (Italy): 198 controls and 198 cases. It should be noted that the total resource consisted of 1017 COPD patients and 912 controls. If strict criteria for genotyping were not met or assay design proved difficult, results were not included in the present analysis to minimise potential errors. This resulted in completed unequivocal genotypes in 977 COPD patients and 876 controls.</p><p>Briefly, recruitment criteria were agreed by a panel of respiratory physicians with an interest in COPD and included a firm clinical diagnosis of COPD; airflow limitation as indicated by (Forced Expiratory Volume in 1 Second) FEV<sub>1 </sub>&#x02264; 70% normal predicted values and FEV<sub>1</sub>/(Forced Vital Capacity) FVC &#x0003c; 0.7; no significant reversibility with salbutamol (&#x02265; 200 &#x003bc;g) and a smoking history of &#x02265; 20 pack years with matched smoking history for the controls. FEV<sub>1 </sub>is measured using a spirometer, it is the maximum volume of air that can be forcibly breathed out in one second after full inspiration. FVC is the maximum volume of air that can be forcibly breathed out after full inspiration.</p><p>Patients were excluded from the study if they had an established diagnosis of asthma, lung cancer, history of atopy, known AAT deficiency or a serum AAT level of less than 1.0 g/L. Patients with acute exacerbations four weeks preceding study assessment were also excluded. This was an agreed part of the protocol to enable future studies, where appropriate, to investigate correlations of genotypes with quantitative traits such as lung function or concentrations of analytes in biological fluids. We did not recruit any patients with Global Obstructive Lung Disease (GOLD) Stage I. Disease severity was classified according to GOLD as follows: GOLD Stage II (moderate disease): FEV<sub>1</sub>/FVC ratio of &#x0003c; 0.70 and FEV<sub>1 </sub>predicted &#x02265; 50% and &#x0003c; 80%; GOLD Stage III (severe disease): FEV<sub>1</sub>/FVC ratio of &#x0003c; 0.70 and FEV<sub>1 </sub>predicted &#x02265; 30% and &#x0003c; 50%; and GOLD Stage IV (very severe disease): FEV<sub>1</sub>/FVC ratio of &#x0003c; 0.70 and FEV<sub>1 </sub>predicted &#x0003c; 30% [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Control subjects with no evidence of airflow obstruction (FEV<sub>1 </sub>and FVC &#x02265; 80% and FEV<sub>1</sub>/FVC &#x0003e; 0.70) were recruited at each centre with attempted matching to COPD patients for ethnicity, age, gender and smoking history. Exclusion criteria were as described for cases and additionally included family history of COPD. However, complete matching was not achieved due to a high proportion of smokers aged 65 or over having evidence of some pulmonary obstruction, thereby excluding them from recruitment as controls.</p><p>We compared the frequencies of <italic>MMP </italic>SNPs for each centre in cases and controls to look for population stratification. For the genes under study, population stratification would have been reflected in different frequencies in the centre to centre comparisons. No such differences were observed. These findings are in keeping with previous observations on this sample set [<xref ref-type="bibr" rid="B19">19</xref>] and with data obtained from British samples reported by the Wellcome Trust Case Control Consortium in genome- wide association studies where stratification has been shown to be not as significant an issue in the British population as previously thought [<xref ref-type="bibr" rid="B21">21</xref>]; similar findings are likely for western European populations.</p></sec><sec><title>Study Population Characteristics</title><p>The study population characteristics are summarised in Table <xref ref-type="table" rid="T2">2</xref>. Despite attempts to match cases and controls there were significant differences observed and adjustments were made by logistic regression to take this into account in the statistical analysis. The characteristics of recruited COPD patients across the GOLD severity categories are shown in Table <xref ref-type="table" rid="T3">3</xref>.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Characteristics of Controls and COPD subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left">Control</th><th align="left">COPD</th><th align="right">P-value</th></tr></thead><tbody><tr><td align="left"><bold>Male (%)</bold></td><td align="left">63.2</td><td align="left">69.9</td><td align="right">0.3554</td></tr><tr><td align="left"><bold>Age (yr)</bold></td><td align="left">60.7 &#x000b1; 8.9</td><td align="left">65.9 &#x000b1; 8.2</td><td align="right">&#x0003c; 0.0001</td></tr><tr><td align="left"><bold>Smoking Pack Years</bold></td><td align="left">38.6 &#x000b1; 17.4</td><td align="left">48.7 &#x000b1; 22.8</td><td align="right">&#x0003c; 0.0001</td></tr><tr><td align="left"><bold>Predicted FEV<sub>1 </sub>(%)</bold></td><td align="left">95.4 &#x000b1; 11.0</td><td align="left">43.0 &#x000b1; 15.1</td><td align="right">&#x0003c; 0.0001</td></tr><tr><td align="left"><bold>FEV<sub>1</sub>/FVC (%)</bold></td><td align="left">77.8 &#x000b1; 4.9</td><td align="left">47.4 &#x000b1; 12.1</td><td align="right">&#x0003c; 0.0001</td></tr><tr><td align="left"><bold>N</bold></td><td align="left">876</td><td align="left">977</td><td/></tr></tbody></table><table-wrap-foot><p>Values indicated are means &#x000b1; SD. Pack Years missing for 6 persons.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Characteristics of COPD patients according to GOLD classification of disease severity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">GOLD Status</th><th align="left">II<break/>Moderate</th><th align="left">III<break/>Severe</th><th align="left">IV<break/>Very Severe</th><th align="left">P-value</th></tr></thead><tbody><tr><td align="left"><bold>Male (%)</bold></td><td align="left">74.7</td><td align="left">67.5</td><td align="left">67.2</td><td align="left">0.0608</td></tr><tr><td align="left"><bold>Age (yr)</bold></td><td align="left">66.1 &#x000b1; 8.0</td><td align="left">66.7 &#x000b1; 8.4</td><td align="left">64.3 &#x000b1; 8.1</td><td align="left">0.0016</td></tr><tr><td align="left"><bold>Pack Years</bold></td><td align="left">49.2 &#x000b1; 21.1</td><td align="left">48.5 &#x000b1; 22.3</td><td align="left">48.4 &#x000b1; 26.0</td><td align="left">0.9105</td></tr><tr><td align="left"><bold>Predicted FEV<sub>1 </sub>(%)</bold></td><td align="left">60.2 &#x000b1; 5.9</td><td align="left">40.0 &#x000b1; 5.8</td><td align="left">23.4 &#x000b1; 4.3</td><td align="left">&#x0003c; 0.0001</td></tr><tr><td align="left"><bold>FEV<sub>1</sub>/FVC (%)</bold></td><td align="left">57.1 &#x000b1; 7.8</td><td align="left">45.9 &#x000b1; 9.9</td><td align="left">36.2 &#x000b1; 9.4</td><td align="left">&#x0003c; 0.0001</td></tr><tr><td align="left"><bold>N</bold></td><td align="left">336</td><td align="left">406</td><td align="left">235</td><td/></tr></tbody></table><table-wrap-foot><p>Values indicated are means &#x000b1; SD. Pack years missing for 3, 2, 1 persons per classification respectively.</p></table-wrap-foot></table-wrap></sec><sec><title>Power Calculations</title><p>Using Quanto software for the power calculations, with an autosomal dominant model, this study has 80% power to detect an odds ratio of 1.5 with an allele frequency of 0.1.</p></sec><sec><title>SNP Selection and Haplotypes</title><p>SNP identification within <italic>MMP</italic>s- 1, 9 and 12 genes was carried out using information obtained from a combination of databases including HapMap and Seattle SNPs. SNPs with a minor allele frequency of less than 5% were excluded from the study, as these were likely to be insufficiently powered to detect association. SNPs lacking any validation status as described on the dbSNP database were also excluded. Further narrowing of SNP selection was based on putative function described in the databases and predicted function by the FastSNP web-service [<xref ref-type="bibr" rid="B22">22</xref>]. Where SNPs were in linkage disequilibrium (r<sup>2 </sup>&#x02265; 0.8) in previously reported Caucasian populations (HapMap, National Heart Lung and Blood Institute's (NHLBI) Programs for Genomic Applications European (PGA EUR) population, or Environmental Gene Project Centre d'Etude du Polymorphisme Humain (EGP CEPH) European population) a single tagging SNP was chosen for genotyping, thus minimising the number of SNPs that needed to be investigated and reducing the number of statistical tests required. This resulted in 26 SNPs across the three genes being selected for analysis. Information on the 26 genotyped SNPs is indicated in Table <xref ref-type="table" rid="T4">4</xref>. The SNPs were selected as described below.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>SNPs selected for genotyping</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center"><bold>SNP No</bold>.</th><th align="left">Gene</th><th align="left">Locus</th><th align="left">tagged SNPs</th><th align="left">Location in Gene</th><th align="right">Contig position</th><th align="left">Major/Minor allele</th></tr></thead><tbody><tr><td align="center"><bold>1</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs2071230</td><td align="left">rs7125320</td><td align="left">3' UTR</td><td align="right">18098075</td><td align="right">A/G</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">18095326</td><td align="right">G/T</td></tr><tr><td align="center"><bold>2</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs2239008</td><td align="left">rs2071232</td><td align="left">3' UTR</td><td align="right">18097954</td><td align="right">G/A</td></tr><tr><td/><td/><td/><td align="left">rs996999</td><td align="left">Intronic</td><td align="right">18093365</td><td align="right">T/C</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">18091971</td><td align="right">C/T</td></tr><tr><td align="center"><bold>3</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs470215</td><td align="left">rs5854</td><td align="left">3' UTR</td><td align="right">18097935</td><td align="right">A/G</td></tr><tr><td/><td/><td/><td align="left">rs470747</td><td align="left">3' UTR</td><td align="right">18098160</td><td align="right">C/T</td></tr><tr><td/><td/><td/><td align="left">rs470132</td><td align="left">Intronic</td><td align="right">18097439</td><td align="right">T/C</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">18092477</td><td align="right">G/T</td></tr><tr><td align="center"><bold>4</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs1938901</td><td align="left">rs5031036</td><td align="left">Intronic</td><td align="right">18097369</td><td align="right">C/T</td></tr><tr><td align="center"><bold>5</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs17881293</td><td/><td align="left">Intronic</td><td align="right">18096568</td><td align="right">A/G</td></tr><tr><td align="center"><bold>6</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs17884110</td><td/><td align="left">Intronic</td><td align="right">18095557:18095558</td><td align="right">-/C</td></tr><tr><td align="center"><bold>7</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs17878931</td><td/><td align="left">Intronic</td><td align="right">18092379</td><td align="right">C/A</td></tr><tr><td align="center"><bold>8</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs10488</td><td/><td align="left">Exonic</td><td align="right">18091012</td><td align="right">G/A</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">18092870</td><td align="right">A/G</td></tr><tr><td align="center"><bold>9</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs470358</td><td align="left">rs505770</td><td align="left">Intronic</td><td align="right">18090333</td><td align="right">C/T</td></tr><tr><td align="center"><bold>10</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs3213460</td><td align="left">rs476391</td><td align="left">5'UTR</td><td align="right">18090153</td><td align="right">G/A</td></tr><tr><td align="center"><bold>11</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs514921</td><td align="left">rs644552</td><td align="left">Promoter</td><td align="right">18089805</td><td align="right">A/G</td></tr><tr><td align="center"><bold>12</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs498186</td><td align="left">rs651159</td><td align="left">Promoter</td><td align="right">18089390</td><td align="right">A/C</td></tr><tr><td align="center"><bold>13</bold></td><td align="left"><italic>MMP-1</italic></td><td align="left">rs1799750</td><td align="left">rs662028</td><td align="left">Promoter</td><td align="right">18088538:18088539</td><td align="right">-/G</td></tr><tr><td align="center"><bold>14</bold></td><td align="left"><italic>MMP-12</italic></td><td align="left">rs652438</td><td/><td align="left">Exonic (Asn357Ser)</td><td align="right">18022346</td><td align="right">A/G</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">18024778</td><td align="right">T/A</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">18023958</td><td align="right">G/C</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">18023848</td><td align="right">G/A</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">18022569</td><td align="right">A/G</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">18018358</td><td align="right">A/G</td></tr><tr><td align="center"><bold>15</bold></td><td align="left"><italic>MMP-12</italic></td><td align="left">rs632009</td><td align="left">rs7123600</td><td align="left">Intronic</td><td align="right">18020490</td><td align="right">C/T</td></tr><tr><td/><td/><td/><td align="left">rs10895367</td><td align="left">Intronic</td><td align="right">18017018</td><td align="right">A/G</td></tr><tr><td align="center"><bold>16</bold></td><td align="left"><italic>MMP-12</italic></td><td align="left">rs11225442</td><td/><td align="left">Intronic</td><td align="right">18019669</td><td align="right">G/A</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">18013855</td><td align="right">G/C</td></tr><tr><td align="center"><bold>17</bold></td><td align="left"><italic>MMP-12</italic></td><td align="left">rs28381675</td><td align="left">rs28381684</td><td align="left">Intronic</td><td align="right">18018010</td><td align="right">A/G</td></tr><tr><td align="center"><bold>18</bold></td><td align="left"><italic>MMP-12</italic></td><td align="left">rs2276109</td><td align="left">rs17368582</td><td align="left">Upstream</td><td align="right">18013194</td><td align="right">A/G</td></tr><tr><td/><td/><td/><td align="left">rs17368659</td><td align="left">Intronic</td><td align="right">18021796</td><td align="right">T/A</td></tr><tr><td/><td/><td/><td/><td align="left">Exonic</td><td align="right">18020914</td><td align="right">T/C</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">18016225</td><td align="right">G/T</td></tr><tr><td align="center"><bold>19</bold></td><td align="left"><italic>MMP-9</italic></td><td align="left">rs3918262</td><td align="left">rs3787268</td><td align="left">Intronic</td><td align="right">7706054</td><td align="right">A/G</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">7704015</td><td align="right">G/A</td></tr><tr><td align="center"><bold>20</bold></td><td align="left"><italic>MMP-9</italic></td><td align="left">rs13969</td><td align="left">rs20544</td><td align="left">Exonic</td><td align="right">7705117</td><td align="right">C/A</td></tr><tr><td align="center"><bold>21</bold></td><td align="left"><italic>MMP-9</italic></td><td align="left">rs2250889</td><td align="left">rs3918251</td><td align="left">Exonic (Pro574Arg)</td><td align="right">7704690</td><td align="right">C/G</td></tr><tr><td align="center"><bold>22</bold></td><td align="left"><italic>MMP-9</italic></td><td align="left">rs3918256</td><td align="left">rs3918253</td><td align="left">Intronic</td><td align="right">7703243</td><td align="right">A/G</td></tr><tr><td/><td/><td/><td align="left">rs8113877</td><td align="left">3' UTR</td><td align="right">7707164</td><td align="right">C/T</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">7701053</td><td align="right">A/G</td></tr><tr><td/><td/><td/><td/><td align="left">Intronic</td><td align="right">7701795</td><td align="right">T/C</td></tr><tr><td/><td/><td/><td/><td align="left">Upstream</td><td align="right">7697335</td><td align="right">T/G</td></tr><tr><td align="center"><bold>23</bold></td><td align="left"><italic>MMP-9</italic></td><td align="left">rs17576</td><td align="left">rs3918249</td><td align="left">Exonic (Gln279Arg)</td><td align="right">7702509</td><td align="right">A/G</td></tr><tr><td/><td/><td/><td align="left">rs3918240</td><td align="left">Intronic</td><td align="right">7700408</td><td align="right">C/T</td></tr><tr><td/><td/><td/><td align="left">rs6965913</td><td align="left">Upstream</td><td align="right">7697906</td><td align="right">C/T</td></tr><tr><td/><td/><td/><td/><td align="left">Upstream</td><td align="right">7697393</td><td align="right">C/T</td></tr><tr><td align="center"><bold>24</bold></td><td align="left"><italic>MMP-9</italic></td><td align="left">rs2274755</td><td align="left">rs3918242</td><td align="left">Intronic</td><td align="right">7701976</td><td align="right">G/T</td></tr><tr><td/><td/><td/><td align="left">rs13925</td><td align="left">Promoter</td><td align="right">7968266</td><td align="right">C/T</td></tr><tr><td/><td/><td/><td align="left">rs3918261</td><td align="left">Exonic</td><td align="right">7707119</td><td align="right">G/A</td></tr><tr><td/><td/><td/><td align="left">rs17577</td><td align="left">Intronic</td><td align="right">7705876</td><td align="right">A/G</td></tr><tr><td/><td/><td/><td/><td align="left">Exonic (Arg668Gln)</td><td align="right">7705395</td><td align="right">G/A</td></tr><tr><td/><td/><td/><td align="left">rs2236416</td><td align="left">Intronic</td><td align="right">7702859</td><td align="right">A/G</td></tr><tr><td/><td/><td/><td align="left">rs3918241</td><td align="left">Upstream</td><td align="right">7698025</td><td align="right">T/A</td></tr><tr><td align="center"><bold>25</bold></td><td align="left"><italic>MMP-9</italic></td><td align="left">rs3918278</td><td/><td align="left">Upstream</td><td align="right">7697944</td><td align="right">G/A</td></tr><tr><td align="center"><bold>26</bold></td><td align="left"><italic>MMP-9</italic></td><td align="left">rs11697325</td><td/><td align="left">Upstream</td><td align="right">7691635</td><td align="right">A/G</td></tr></tbody></table><table-wrap-foot><p>SNPs are shown in 3' to 5' order. Contig Position numbering is relative to HuRef NCBI build 36.3. SNPs 6 and 13 (rs numbers 17884110 and 1799750 respectively) represent an insertion/deletion polymorphism. Amino acid changes are shown where present.</p></table-wrap-foot></table-wrap><sec><title>MMP-1</title><p>A panel of 21 validated SNPs was identified within the gene and its promoter region. However, rs488178 was found to be unsuitable for design and was excluded. Consideration of the linkage disequilibrium between the SNPs resulted in a final panel of 13 SNPs being genotyped, giving 87% coverage of validated SNP variation in <italic>MMP-1</italic>.</p></sec><sec><title>MMP-9</title><p>A panel of 23 validated SNPs was identified within the gene and its promoter region from the databases, which covered all known validated SNPs within the region. However, rs25650 was found to be non-polymorphic in the study cohort and was excluded from further analysis. Consideration of the linkage disequilibrium between the SNPs resulted in a final panel of 8 tagged SNPs being genotyped, giving 96% coverage of validated SNP variation in <italic>MMP-9</italic>.</p></sec><sec><title>MMP-12</title><p>A panel of 17 validated SNPs was identified within the gene and its promoter region, a selection which covered all known validated SNPs within the region. However, rs28360355, rs28381675 and rs28360356 were found to be unsuitable for assay design and were excluded. Consideration of the linkage disequilibrium between the SNPs resulted in a final panel of five SNPs being genotyped, giving 82% coverage of validated SNP variation in <italic>MMP-12</italic>.</p></sec></sec><sec><title>Genotyping of Study Samples</title><p>Full genotyping information was available in 977 COPD cases and 876 controls. Genotyping was carried out commercially by K- Bioscience using KASPar, an in-house validated competitive allele-specific polymerase chain reaction SNP genotyping system which utilises fluorescence resonance energy transfer quencher cassette oligonucleotides. Taqman, a rapid fluorophore based real- time PCR method, was used to genotype SNPs found to be unsuitable for KASPar assay design. As a quality control measure, approximately 5% of samples were genotyped in duplicate to check for concordance. There was 100% concordance between the duplicates, satisfying criteria for the assays to be accepted for further analysis.</p></sec><sec><title>Statistical Analysis</title><p>Each of the SNPs in the three genes was analyzed for Hardy-Weinberg equilibrium (HWE) using PROC ALLELE in SAS/Genetics Release 9.1.3 [<xref ref-type="bibr" rid="B23">23</xref>], an empirical p-value of &#x02264; 0.01 was used as a cut-off, to reduce the likelihood of reporting false positives. To examine linkage disequilibrium, the correlation coefficient between SNP pairs within each gene in cases and controls was calculated using Haploview 4.1 [<xref ref-type="bibr" rid="B24">24</xref>] a software package that computes linkage disequilibrium and haplotype blocks from genotype data (figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>LD plot in controls of SNPs in MMPs- 1, 9 and 12</bold>. Estimated as r<sup>2 </sup>using Haploview 4.1 output. SNP codes are provided in order of location along each gene; dark grey squares depict strong LD (1.0) with strong confidence, pale grey and white regions represent low LD, and the r<sup>2 </sup>value is provided within each box. SNP positions are demonstrated 5' to 3' relative to contig postion (HuRef NCBI build 36.3).</p></caption><graphic xlink:href="1471-2350-11-7-1"/></fig><p>Analyses of allele and genotype frequencies for the three <italic>MMP </italic>genes were performed using PROC ALLELE in SAS/Genetics. The adjusted p-values for genotype and allele frequencies were obtained using PROC LOGISTIC in SAS, adjusting for age, sex, smoking and centre.</p><p>As haplotypes of <italic>MMP</italic>s have been reported to be associated with COPD or decline in lung function [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B25">25</xref>], using FAMHAP18 [<xref ref-type="bibr" rid="B26">26</xref>] we examined haplotypes in all possible SNP combinations based on the eight SNPs in the <italic>MMP-9 </italic>gene on chromosome 20 and also in all combinations consisting of four or fewer SNPs from the 16 analysable SNPs (see below) in <italic>MMP-1 </italic>and <italic>MMP</italic>-<italic>12 </italic>combined on Chromosome 11. We considered only up to four haplotypes because of the optimal power considerations in FAMHAP18. We compared haplotype distributions for all cases versus controls, for GOLD severity III and IV cases versus controls and for GOLD severity IV only versus controls. We used as a cut off criterion a p &#x0003c; 0.01 for a significance test on the contingency table of all possible simulated haplotypes within possible SNP combination in cases and controls.</p><p>P-values were based on 10,000 simulations and since for this sample size the 95% confidence limits for 0.01 are +/- 0.002, we report all comparisons with a p-value less than 0.012. To allow for multiple testing we used the maximum estimated q-value that corresponds to p-values &#x02264; 0.012 with a high stringency estimate of the false discovery rate (FDR) [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>] (using the q-value Package in R [<xref ref-type="bibr" rid="B29">29</xref>]).</p><p>Odds ratios for haplotype and individual SNP allele distributions are relative to the common haplotype or allele. The adjusted odds ratios with 95% confidence intervals, adjusting for age, sex, smoking and centre are estimated for haplotypes by weighted logistic regression as described previously [<xref ref-type="bibr" rid="B19">19</xref>] (PROC LOGISTIC in SAS), and for alleles by standard logistic regression.</p><p>Using PROC GLM in SAS [<xref ref-type="bibr" rid="B23">23</xref>] the quantitative trait associations between SNPs or haplotypes and the phenotype FEV<sub>1 </sub>were tested by multivariate regression using a similar weighted method to that used in logistic regression [<xref ref-type="bibr" rid="B19">19</xref>], adjusting for age, sex, smoking and centre. The adjusted means were determined using the LSMEANS option.</p></sec></sec><sec><title>Results</title><sec><title>Quality Control</title><p>The full list of SNPs analysed are shown in Table <xref ref-type="table" rid="T4">4</xref>. The overall genotype call rate was 95% (range, 92-96%), and the accuracy was 100% according to duplicate genotyping of &#x0003e; 5% of samples. The use of high stringency cut-offs resulted in the loss of some genotyping data and reduction in the number of patients studied from the original sample set. Significant deviation from HWE was observed in controls for two <italic>MMP-1 </italic>SNPs, rs470358 and rs2071230. The assays for these two SNPs were sub-optimal, with overlap in the signals observed for homozygotes and hetrozygotes.</p></sec><sec><title>Association Analysis</title><p>Table <xref ref-type="table" rid="T5">5</xref> compares the genotype frequencies between all cases and controls for the 26 SNPs analysed. There were no significant differences at p &#x0003c; 0.01 in either the crude analysis or the analysis adjusted for age, sex, smoking levels and centre. To evaluate potential genetic contribution to more severe manifestations of the disease, those with moderate levels of disease were excluded from the cases and patients with either severe or very severe disease (GOLD groups III and IV) were compared to controls. This comparison was also performed for cases with very severe disease only (GOLD group IV). This approach enabled evaluation of the potential underlying genetic contribution to disease severity phenotype within the study population with least reduction in power. While unadjusted analysis indicated significant associations between genotype frequencies of SNP 18 and more severe disease, these became non-significant with p &#x0003e; 0.01 when adjusted for age, sex, smoking and centre (Table <xref ref-type="table" rid="T5">5</xref>). Table <xref ref-type="table" rid="T6">6</xref> analyses allele relationships for all SNPs.</p><table-wrap id="T5" position="float"><label>Table 5</label><caption><p><italic>MMP</italic>s -<italic>1, 12 and 9 </italic>- Genotype frequencies in Controls and Cases</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left"><bold>SNP No</bold>.</th><th align="left">Locus</th><th align="left">Genotypes</th><th align="left">Controls</th><th align="left">COPD<break/>all cases</th><th align="left">Unadjusted<break/>P-value</th><th align="left">Adjusted P-value**</th></tr></thead><tbody><tr><td align="left"><bold><italic>MMP</italic>1</bold></td><td align="left"><bold>1</bold></td><td align="left"><bold>rs2071230</bold></td><td align="left">AA/AG/GG</td><td align="left">0.85/0.13/0.02</td><td align="left">0.85/0.14/0.00</td><td align="left">0.01</td><td align="left">0.16</td></tr><tr><td/><td align="left"><bold>2</bold></td><td align="left"><bold>rs2239008</bold></td><td align="left">GG/GA/AA</td><td align="left">0.64/0.33/0.03</td><td align="left">0.64/0.31/0.05</td><td align="left">0.26</td><td align="left">0.28</td></tr><tr><td/><td align="left"><bold>3</bold></td><td align="left"><bold>rs470215</bold></td><td align="left">AA/AG/GG</td><td align="left">0.39/0.47/0.14</td><td align="left">0.40/0.47/0.13</td><td align="left">0.61</td><td align="left">0.86</td></tr><tr><td/><td align="left"><bold>4</bold></td><td align="left"><bold>rs1938901</bold></td><td align="left">CC/CT/TT</td><td align="left">0.51/0.41/0.08</td><td align="left">0.48/0.42/0.10</td><td align="left">0.25</td><td align="left">0.22</td></tr><tr><td/><td align="left"><bold>5</bold></td><td align="left"><bold>rs17881293</bold></td><td align="left">AA/AG/GG</td><td align="left">0.89/0.10/0.01</td><td align="left">0.89/0.11/0.00</td><td align="left">0.65</td><td align="left">0.74</td></tr><tr><td/><td align="left"><bold>6</bold></td><td align="left"><bold>rs17884110</bold></td><td align="left">C/C/C</td><td align="left">0.39/0.47/0.14</td><td align="left">0.41/0.47/0.12</td><td align="left">0.42</td><td align="left">0.78</td></tr><tr><td/><td align="left"><bold>7</bold></td><td align="left"><bold>rs17878931</bold></td><td align="left">AA/AC/CC</td><td align="left">0.01/0.25/0.74</td><td align="left">0.02/0.25/0.73</td><td align="left">0.66</td><td align="left">0.33</td></tr><tr><td/><td align="left"><bold>8</bold></td><td align="left"><bold>rs10488</bold></td><td align="left">GG/GA/AA</td><td align="left">0.89/0.11/0.01</td><td align="left">0.88/0.11/0.00</td><td align="left">0.6</td><td align="left">0.75</td></tr><tr><td/><td align="left"><bold>9</bold></td><td align="left"><bold>rs470358</bold></td><td align="left">TT/TC/CC</td><td align="left">0.14/0.40/0.46</td><td align="left">0.17/0.37/0.46</td><td align="left">0.32</td><td align="left">0.54</td></tr><tr><td/><td align="left"><bold>10</bold></td><td align="left"><bold>rs3213460</bold></td><td align="left">GG/GA/AA</td><td align="left">0.73/0.25/0.02</td><td align="left">0.72/0.26/0.02</td><td align="left">0.84</td><td align="left">0.43</td></tr><tr><td/><td align="left"><bold>11</bold></td><td align="left"><bold>rs514921</bold></td><td align="left">AA/AG/GG</td><td align="left">0.50/0.42/0.08</td><td align="left">0.50/0.42/0.08</td><td align="left">0.99</td><td align="left">0.94</td></tr><tr><td/><td align="left"><bold>12</bold></td><td align="left"><bold>rs498186</bold></td><td align="left">AA/AC/CC</td><td align="left">0.28/0.52/0.20</td><td align="left">0.29/0.48/0.23</td><td align="left">0.13</td><td align="left">0.39</td></tr><tr><td/><td align="left"><bold>13</bold></td><td align="left"><bold>rs1799750</bold></td><td align="left">G/G/G</td><td align="left">0.26/0.52/0.22</td><td align="left">0.28/0.47/0.25</td><td align="left">0.13</td><td align="left">0.45</td></tr><tr><td align="left"><bold><italic>MMP</italic>12</bold></td><td align="left"><bold>14</bold></td><td align="left"><bold>rs652438</bold></td><td align="left">AA/AG/GG</td><td align="left">0.90/0.10/0.00</td><td align="left">0.90/0.09/0.00</td><td align="left">0.34</td><td align="left">0.87</td></tr><tr><td/><td align="left"><bold>15</bold></td><td align="left"><bold>rs632009</bold></td><td align="left">CC/CT/TT</td><td align="left">0.45/0.44/0.11</td><td align="left">0.46/0.42/0.12</td><td align="left">0.53</td><td align="left">0.34</td></tr><tr><td/><td align="left"><bold>16</bold></td><td align="left"><bold>rs11225442</bold></td><td align="left">GG/GA/AA</td><td align="left">0.75/0.23/0.02</td><td align="left">0.76/0.22/0.02</td><td align="left">0.8</td><td align="left">0.79</td></tr><tr><td/><td align="left"><bold>17</bold></td><td align="left"><bold>rs28381675</bold></td><td align="left">AA/AG/GG</td><td align="left">0.88/0.11/0.00</td><td align="left">0.87/0.12/0.01</td><td align="left">0.5</td><td align="left">0.22</td></tr><tr><td/><td align="left"><bold>18</bold></td><td align="left"><bold>rs2276109</bold></td><td align="left">AA/AG/GG</td><td align="left">0.75/0.24/0.01</td><td align="left">0.80/0.19/0.02</td><td align="left">0.02</td><td align="left">0.12</td></tr><tr><td align="left"><bold><italic>MMP</italic>9</bold></td><td align="left"><bold>19</bold></td><td align="left"><bold>rs3918262</bold></td><td align="left">AA/AG/GG</td><td align="left">0.66/0.31/0.03</td><td align="left">0.63/0.32/0.05</td><td align="left">0.12</td><td align="left">0.15</td></tr><tr><td/><td align="left"><bold>20</bold></td><td align="left"><bold>rs13969</bold></td><td align="left">CC/CA/AA</td><td align="left">0.38/0.47/0.15</td><td align="left">0.37/0.47/0.16</td><td align="left">0.79</td><td align="left">0.83</td></tr><tr><td/><td align="left"><bold>21</bold></td><td align="left"><bold>rs2250889</bold></td><td align="left">CC/CG/GG</td><td align="left">0.93/0.07/0.01</td><td align="left">0.93/0.07/0.00</td><td align="left">0.45</td><td align="left">0.68</td></tr><tr><td/><td align="left"><bold>22</bold></td><td align="left"><bold>rs3918256</bold></td><td align="left">AA/AG/GG</td><td align="left">0.36/0.47/0.17</td><td align="left">0.35/0.48/0.17</td><td align="left">0.83</td><td align="left">0.64</td></tr><tr><td/><td align="left"><bold>23</bold></td><td align="left"><bold>rs17576</bold></td><td align="left">AA/AG/GG</td><td align="left">0.43/0.45/0.12</td><td align="left">0.42/0.45/0.13</td><td align="left">0.62</td><td align="left">0.58</td></tr><tr><td/><td align="left"><bold>24</bold></td><td align="left"><bold>rs2274755</bold></td><td align="left">GG/GT/TT</td><td align="left">0.71/0.26/0.02</td><td align="left">0.73/0.25/0.02</td><td align="left">0.69</td><td align="left">0.79</td></tr><tr><td/><td align="left"><bold>25</bold></td><td align="left"><bold>rs3918278</bold></td><td align="left">GG/GA/AA</td><td align="left">0.96/0.04/0.00</td><td align="left">0.95/0.05/0.00</td><td align="left">0.46</td><td align="left">0.13</td></tr><tr><td/><td align="left"><bold>26</bold></td><td align="left"><bold>rs11697325</bold></td><td align="left">AA/AG/GG</td><td align="left">0.39/0.46/0.15</td><td align="left">0.37/0.47/0.16</td><td align="left">0.64</td><td align="left">0.64</td></tr><tr><td colspan="8"><hr/></td></tr><tr><td align="left"><bold>Gene</bold></td><td align="left"><bold>SNP No</bold>.</td><td align="left"><bold>Locus</bold></td><td align="left"><bold>Genotypes</bold></td><td align="left"><bold>Controls</bold></td><td align="left"><bold>COPD</bold><break/><bold>Severity IV*</bold></td><td align="left"><bold>Unadjusted</bold><break/><bold>P-value</bold></td><td align="left"><bold>Adjusted P-value**</bold></td></tr><tr><td align="left"><bold><italic>MMP12</italic></bold></td><td align="left"><bold>18</bold></td><td align="left"><bold>rs2276109</bold></td><td align="left">AA/AG/GG</td><td align="left">0.75/0.24/0.01</td><td align="left">0.83/0.15/0.02</td><td align="left">0.008</td><td align="left">0.03</td></tr><tr><td colspan="8"><hr/></td></tr><tr><td align="left"><bold>Gene</bold></td><td align="left"><bold>SNP No</bold>.</td><td align="left"><bold>Locus</bold></td><td align="left"><bold>Genotypes</bold></td><td align="left"><bold>Controls</bold></td><td align="left"><bold>COPD</bold><break/><bold>Severity</bold><break/><bold>III and IV*</bold></td><td align="left"><bold>Unadjusted</bold><break/><bold>P-value</bold></td><td align="left"><bold>Adjusted P-value**</bold></td></tr><tr><td align="left"><bold><italic>MMP12</italic></bold></td><td align="left"><bold>18</bold></td><td align="left"><bold>rs2276109</bold></td><td align="left">AA/AG/GG</td><td align="left">0.75/0.24/0.01</td><td align="left">0.81/0.17/0.01</td><td align="left">0.007</td><td align="left">0.08</td></tr></tbody></table><table-wrap-foot><p>*For GOLD classification severity III and IV, and severity IV, only SNPs with an unadjusted significant (p-value &#x02264; 0.01) genotypes difference between cases and controls are reported.</p><p>** P-values adjusted by logistic regression for age, sex, smoking and centre.</p></table-wrap-foot></table-wrap><table-wrap id="T6" position="float"><label>Table 6</label><caption><p><italic>MMP</italic>s -<italic>1, 12 and 9 </italic>- Allelic frequencies in Controls and Cases</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left"><bold>SNP No</bold>.</th><th align="center">Locus</th><th align="center">Major/Minor<break/>Alleles</th><th align="center" colspan="2">Minor Allele Frequencies</th><th align="center">Unadjusted<break/>P-value</th><th align="center">Adjusted<break/>P-value*</th><th align="center">Adjusted<break/>Odds Ratio**</th></tr><tr><th/><th/><th/><th/><th align="center">Controls</th><th align="center">COPD<break/>all cases</th><th/><th/><th/></tr></thead><tbody><tr><td align="left"><bold><italic>MMP</italic>1</bold></td><td align="left"><bold>1</bold></td><td align="center"><bold>rs2071230</bold></td><td align="center">A/G</td><td align="center">0.08</td><td align="center">0.07</td><td align="center">0.4354</td><td align="center">0.7453</td><td align="center">1.045</td></tr><tr><td/><td align="left"><bold>2</bold></td><td align="center"><bold>rs2239008</bold></td><td align="center">G/A</td><td align="center">0.20</td><td align="center">0.20</td><td align="center">0.6539</td><td align="center">0.5193</td><td align="center">0.943</td></tr><tr><td/><td align="left"><bold>3</bold></td><td align="center"><bold>rs470215</bold></td><td align="center">A/G</td><td align="center">0.38</td><td align="center">0.36</td><td align="center">0.3502</td><td align="center">0.5923</td><td align="center">1.041</td></tr><tr><td/><td align="left"><bold>4</bold></td><td align="center"><bold>rs1938901</bold></td><td align="center">C/T</td><td align="center">0.28</td><td align="center">0.31</td><td align="center">0.1248</td><td align="center">0.2060</td><td align="center">0.904</td></tr><tr><td/><td align="left"><bold>5</bold></td><td align="center"><bold>rs17881293</bold></td><td align="center">A/G</td><td align="center">0.06</td><td align="center">0.06</td><td align="center">0.9887</td><td align="center">0.8005</td><td align="center">1.039</td></tr><tr><td/><td align="left"><bold>6</bold></td><td align="center"><bold>rs17884110</bold></td><td align="center">-/C</td><td align="center">0.38</td><td align="center">0.36</td><td align="center">0.2574</td><td align="center">0.5656</td><td align="center">1.044</td></tr><tr><td/><td align="left"><bold>7</bold></td><td align="center"><bold>rs17878931</bold></td><td align="center">C/A</td><td align="center">0.14</td><td align="center">0.14</td><td align="center">0.5514</td><td align="center">0.4245</td><td align="center">0.919</td></tr><tr><td/><td align="left"><bold>8</bold></td><td align="center"><bold>rs10488</bold></td><td align="center">G/A</td><td align="center">0.06</td><td align="center">0.06</td><td align="center">0.9190</td><td align="center">0.7863</td><td align="center">1.042</td></tr><tr><td/><td align="left"><bold>9</bold></td><td align="center"><bold>rs470358</bold></td><td align="center">C/T</td><td align="center">0.34</td><td align="center">0.35</td><td align="center">0.4928</td><td align="center">0.6550</td><td align="center">0.966</td></tr><tr><td/><td align="left"><bold>10</bold></td><td align="center"><bold>rs3213460</bold></td><td align="center">G/A</td><td align="center">0.14</td><td align="center">0.15</td><td align="center">0.5609</td><td align="center">0.2504</td><td align="center">0.889</td></tr><tr><td/><td align="left"><bold>11</bold></td><td align="center"><bold>rs514921</bold></td><td align="center">A/G</td><td align="center">0.29</td><td align="center">0.29</td><td align="center">0.9823</td><td align="center">0.7495</td><td align="center">1.026</td></tr><tr><td/><td align="left"><bold>12</bold></td><td align="center"><bold>rs498186</bold></td><td align="center">A/C</td><td align="center">0.46</td><td align="center">0.47</td><td align="center">0.4443</td><td align="center">0.3265</td><td align="center">0.931</td></tr><tr><td/><td align="left"><bold>13</bold></td><td align="center"><bold>rs1799750</bold></td><td align="center">-/G</td><td align="center">0.48</td><td align="center">0.48</td><td align="center">0.8539</td><td align="center">0.6630</td><td align="center">0.969</td></tr><tr><td align="left"><bold><italic>MMP</italic>12</bold></td><td align="left"><bold>14</bold></td><td align="center"><bold>rs652438</bold></td><td align="center">A/G</td><td align="center">0.05</td><td align="center">0.05</td><td align="center">0.4773</td><td align="center">0.6428</td><td align="center">1.078</td></tr><tr><td/><td align="left"><bold>15</bold></td><td align="center"><bold>rs632009</bold></td><td align="center">C/T</td><td align="center">0.33</td><td align="center">0.33</td><td align="center">0.9704</td><td align="center">0.4266</td><td align="center">1.063</td></tr><tr><td/><td align="left"><bold>16</bold></td><td align="center"><bold>rs11225442</bold></td><td align="center">G/A</td><td align="center">0.13</td><td align="center">0.13</td><td align="center">0.6509</td><td align="center">0.6242</td><td align="center">1.053</td></tr><tr><td/><td align="left"><bold>17</bold></td><td align="center"><bold>rs28381675</bold></td><td align="center">A/G</td><td align="center">0.06</td><td align="center">0.07</td><td align="center">0.3088</td><td align="center">0.0910</td><td align="center">0.784</td></tr><tr><td/><td align="left"><bold>18</bold></td><td align="center"><bold>rs2276109</bold></td><td align="center">A/G</td><td align="center">0.13</td><td align="center">0.11</td><td align="center">0.0659</td><td align="center">0.3243</td><td align="center">1.115</td></tr><tr><td align="left"><bold><italic>MMP</italic>9</bold></td><td align="left"><bold>19</bold></td><td align="center"><bold>rs3918262</bold></td><td align="center">A/G</td><td align="center">0.19</td><td align="center">0.21</td><td align="center">0.0591</td><td align="center">0.0647</td><td align="center">0.846</td></tr><tr><td/><td align="left"><bold>20</bold></td><td align="center"><bold>rs13969</bold></td><td align="center">C/A</td><td align="center">0.38</td><td align="center">0.39</td><td align="center">0.5351</td><td align="center">0.9600</td><td align="center">0.996</td></tr><tr><td/><td align="left"><bold>21</bold></td><td align="center"><bold>rs2250889</bold></td><td align="center">C/G</td><td align="center">0.04</td><td align="center">0.04</td><td align="center">0.4558</td><td align="center">0.3645</td><td align="center">1.185</td></tr><tr><td/><td align="left"><bold>22</bold></td><td align="center"><bold>rs3918256</bold></td><td align="center">A/G</td><td align="center">0.40</td><td align="center">0.41</td><td align="center">0.5548</td><td align="center">0.9810</td><td align="center">1.002</td></tr><tr><td/><td align="left"><bold>23</bold></td><td align="center"><bold>rs17576</bold></td><td align="center">A/G</td><td align="center">0.34</td><td align="center">0.36</td><td align="center">0.3622</td><td align="center">0.4367</td><td align="center">0.943</td></tr><tr><td/><td align="left"><bold>24</bold></td><td align="center"><bold>rs2274755</bold></td><td align="center">G/T</td><td align="center">0.16</td><td align="center">0.14</td><td align="center">0.3908</td><td align="center">0.4962</td><td align="center">1.072</td></tr><tr><td/><td align="left"><bold>25</bold></td><td align="center"><bold>rs3918278</bold></td><td align="center">G/A</td><td align="center">0.02</td><td align="center">0.02</td><td align="center">0.6433</td><td align="center">0.0371</td><td align="center">0.604</td></tr><tr><td/><td align="left"><bold>26</bold></td><td align="center"><bold>rs11697325</bold></td><td align="center">A/G</td><td align="center">0.38</td><td align="center">0.39</td><td align="center">0.3478</td><td align="center">0.5696</td><td align="center">0.959</td></tr></tbody></table><table-wrap-foot><p>*p-values adjusted by logistic regression for age, sex, smoking and centre.</p><p>** Odds ratios are relative to the major allele.</p></table-wrap-foot></table-wrap><p>As described in the Methods, we then examined all possible haplotypes consisting of between two and four SNPs in the same chromosome for differences between the case groups defined above and controls. Adjusting for multiple testing the only significant differences in haplotype distributions were found when severe/very severe (GOLD groups III and IV) cases were involved. Table <xref ref-type="table" rid="T7">7</xref> shows the seven significant haplotypes together with their unadjusted p-values. Since the haplotype comprising SNPs 14 and 18 (p = 0.0086) is a subset of all the other significant combinations identified, we deduce that the significant results are a consequence of the association of SNPs 14 and 18 with disease severity in COPD, despite the apparently high false discovery rate of 0.54. The low LD (r<sup>2 </sup>= 0.083) in controls between these two SNPs indicates the separate involvement of both SNPs in this association.</p><table-wrap id="T7" position="float"><label>Table 7</label><caption><p><italic>MMP - 1 and 12 </italic>Risk Haplotypes related to disease GOLD severity III and IV combined versus controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center" colspan="7">SNP No</th><th align="center">P-value<sup>+</sup></th></tr><tr><th/><th colspan="7"><hr/></th><th/></tr><tr><th align="left">Haplotypes</th><th align="center">6</th><th align="center">10</th><th align="center">12</th><th align="center">13</th><th align="center">14</th><th align="center">16</th><th align="center">18</th><th/></tr></thead><tbody><tr><td align="left"><bold>2-SNP</bold></td><td/><td/><td/><td/><td align="center">x</td><td/><td align="center">x</td><td align="center">0.0086</td></tr><tr><td align="left"><bold>3-SNP</bold></td><td/><td align="center">x</td><td/><td/><td align="center">x</td><td/><td align="center">x</td><td align="center">0.0116</td></tr><tr><td align="left"><bold>3-SNP</bold></td><td/><td/><td/><td align="center">x</td><td align="center">x</td><td/><td align="center">x</td><td align="center">0.0094</td></tr><tr><td align="left"><bold>3-SNP</bold></td><td/><td/><td/><td/><td align="center">x</td><td align="center">x</td><td align="center">x</td><td align="center">0.0076</td></tr><tr><td align="left"><bold>4-SNP</bold></td><td align="center">x</td><td/><td/><td align="center">x</td><td align="center">x</td><td/><td align="center">x</td><td align="center">0.0110</td></tr><tr><td align="left"><bold>4-SNP</bold></td><td/><td align="center">x</td><td/><td align="center">x</td><td align="center">x</td><td/><td align="center">x</td><td align="center">0.0054</td></tr><tr><td align="left"><bold>4-SNP</bold></td><td/><td/><td align="center">x</td><td/><td align="center">x</td><td align="center">x</td><td align="center">x</td><td align="center">0.0092</td></tr></tbody></table><table-wrap-foot><p><sup>+ </sup>P-values are by Monte-Carlo simulation on 10,000 runs.</p></table-wrap-foot></table-wrap><p>Table <xref ref-type="table" rid="T8">8</xref> shows the actual haplotypes of SNPs 14 and 18 in the <italic>MMP-12 </italic>gene and their frequencies in severe/very severe disease (GOLD Stages III and IV) compared to controls. For completeness the table also shows the relationship of the alleles of each SNP alone with severity. Persons with the rare G allele of either SNPs 14 or 18 were protected against severe/very severe COPD. Compared with the common A-A haplotype of SNPs 14 and 18, subjects with the G allele at either locus had a significantly reduced risk of having severe/very severe COPD. Of note, and of importance from a population perspective, is that, based on the distribution in controls, 18% of the European population have at least one of these protective haplotypes, with an average risk 0.76 (95% CI: 0.61 to 0.94) times less than those with the common haplotype.</p><table-wrap id="T8" position="float"><label>Table 8</label><caption><p><italic>MMP</italic>- <italic>12 </italic>haplotypes significantly different between GOLD Classification III and IV cases and controls</p></caption><table frame="hsides" rules="groups"><tbody><tr><td/><td/><td/><td align="left" colspan="2"><bold>Frequency (%)</bold></td><td/><td/><td/></tr><tr><td/><td/><td align="center"><bold>GOLD</bold><break/><bold>III and IV</bold></td><td align="center"><bold>Controls</bold></td><td align="center"><bold>p-value+</bold></td><td align="center" colspan="3"><bold>Odds Ratio*</bold></td></tr><tr><td/><td/><td align="center"><bold>(n = 641)</bold></td><td align="center"><bold>(n = 876)</bold></td><td/><td align="center"><bold>Unadjusted</bold></td><td align="center"><bold>Adjusted**</bold></td><td align="left"><bold>95% CI</bold></td></tr><tr><td/><td colspan="7"><hr/></td></tr><tr><td align="center"><bold>SNP 14</bold><break/><bold>(rs652438)</bold></td><td align="center"><bold>A</bold></td><td align="center">96.2</td><td align="center">94.7</td><td align="center">0.0536</td><td align="center">1</td><td/><td/></tr><tr><td/><td align="center"><bold>G</bold></td><td align="center">3.8</td><td align="center">5.3</td><td/><td align="center">0.71</td><td align="center">0.76</td><td align="left">0.52 to 1.12</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align="center"><bold>SNP 18</bold><break/><bold>(rs2276109)</bold></td><td align="center"><bold>A</bold></td><td align="center">90.0</td><td align="center">87.0</td><td align="center">0.0112</td><td align="center">1</td><td/><td/></tr><tr><td/><td align="center"><bold>G</bold></td><td align="center">10.0</td><td align="center">13.0</td><td/><td align="center">0.74</td><td align="center">0.79</td><td align="left">0.61 to 1.02</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td align="center"><bold>Haplotypes of SNP 14 and SNP 18</bold></td><td align="center"><bold>A-A</bold></td><td align="center">86.3</td><td align="center">82.0</td><td align="center">0.0086</td><td align="center">1</td><td align="center">1</td><td/></tr><tr><td/><td align="center"><bold>A-G</bold></td><td align="center">9.8</td><td align="center">12.7</td><td/><td align="center">0.73</td><td align="center">0.78</td><td align="left">0.60 to 1.00</td></tr><tr><td/><td align="center"><bold>G-A</bold></td><td align="center">3.8</td><td align="center">5.1</td><td/><td align="center">0.70</td><td align="center">0.74</td><td align="left">0.50 to 1.09</td></tr><tr><td/><td align="center"><bold>G-G</bold></td><td align="center">0.1</td><td align="center">0.2</td><td/><td align="center">0.36</td><td align="center">0.96</td><td align="left">0.09 to 10.63</td></tr><tr><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td/><td align="center"><bold>A-A</bold></td><td align="center">86.3</td><td align="center">82.0</td><td align="center">0.0039<sup>++</sup></td><td align="center">1</td><td/><td/></tr><tr><td/><td align="center"><bold>A-G, G-A or G-G</bold></td><td align="center">13.7</td><td align="center">18.0</td><td/><td align="center">0.72</td><td align="center">0.76</td><td align="left">0.61 to 0.94</td></tr></tbody></table><table-wrap-foot><p><sup>+ </sup>P-values are by Monte-Carlo simulation on 10,000 runs.</p><p><sup>++ </sup>Adjusted for choice of the most significant 2 &#x000d7; 2 table with collapsed data.</p><p>* Odds ratios are relative to the common allele or haplotype.</p><p>** Adjusted for age, sex, smoking and centre.</p></table-wrap-foot></table-wrap><p>Confining the analysis to cases only we examined the relationship between variation in <italic>MMP-12 </italic>SNPs 14 and 18 and their haplotypes to severity of disease using FEV<sub>1 </sub>as a severity measure. Weighted multivariate regression models, adjusting for age, sex, smoking and centre were used to test for the associations. Those individuals with the haplotype A-A had a significantly lower predicted FEV<sub>1 </sub>(42.62% versus 44.79%, p = 0.0129) when compared to patients with any haplotypes containing a G allele. We did not find a significant association between FEV<sub>1 </sub>and the alleles in SNP 14 and SNP 18 singly.</p></sec></sec><sec><title>Discussion</title><p>A number of studies have reported on the role of genetic variants of <italic>MMP</italic>s in genetic susceptibility to COPD or related phenotypes. However, the majority of studies have concentrated on the three well known promoter polymorphisms of these genes - <italic>MMP</italic>1-1607-/G (rs1799750), <italic>MMP</italic>9 -1562 C/T (rs3918242) and the <italic>MMP</italic>12-82A/G (rs2276109) in comparatively smaller sample numbers (Table <xref ref-type="table" rid="T1">1</xref>).</p><p>Our study reports on the largest and most extensive screen of SNPs within the <italic>MMP</italic>s- 1, 9 and 12 genes undertaken to date and include the three promoter SNPs or SNPs that are in LD with the promoter SNPs which have been previously reported, in a larger sample size. All SNPs evaluated in the final analysis were in HWE in controls, had high call rates and concordant duplicates by genotyping, suggesting that this study was not likely to be influenced by genotyping errors. All subjects were of European descent and any potential effects of population stratification were minimised by recruiting patients and controls from each centre and confirmed by the fact that SNP genotype frequencies in the controls for each centre were found to be similar. Given the greater level of power in our study it is unlikely that effects of the magnitude observed in previous, less powered studies, have been missed. However, there may be subtle differences in phenotypes and association with quantitative traits such as lung function decline in the previous studies that we were not able to test. This is in part due to multiple testing issues, investigating numerous phenotypes could lead to false positives. Also, phenotype data for some clinical endpoints such as CT scans for emphysema has not been collected for our population. Although, this may cause difficulties with planning functional work, future work testing associated SNP's in other COPD cohorts characterised for specific phenotypes will address this.</p><p>The patients with very severe disease had a mean age that was less than the severe and moderate groups and this may reflect a survival bias.</p><p>We found that <italic>MMP's </italic>- <italic>1 </italic>and <italic>9 </italic>were not associated with COPD in our populations. This is an interesting result as these genes have previously been implicated in COPD by both rodent and a range of human studies. In the previous case control association studies, many of the associations in MMP's 1 and 9 have been demonstrated in non - Caucasian populations. Further to this, some of the studies use different phenotypic end points.</p><p>For the <italic>MMP</italic>-12 gene, we identified haplotypes associated with two SNPs, SNP 14 (rs652438) and SNP 18 (rs2276109), which showed associations with severe/very severe COPD. The associations with GOLD Stage III and IV disease suggest that these SNPs may play a modifier role in disease severity. We also showed that haplotypes of the two SNPs were significantly related to severity within the COPD cases, as determined by the quantitative levels of FEV1 within the cases. Those with the haplotypes A-G, G-A or G-G had higher FEV1 levels. It is of note that, evaluation of the association of SNP 18 (rs2276109) with COPD has been previously examined, but no effect was seen [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. This probably reflects underpowered studies and the need to examine disease severity. SNP 14 (rs652438) has been previously shown to be associated with smoking induced COPD in a Chinese cohort [<xref ref-type="bibr" rid="B30">30</xref>], as well as being associated with a decline in lung function when considered as a haplotype with the <italic>MMP</italic>-<italic>1 </italic>promoter SNP 13 (rs1799750) [<xref ref-type="bibr" rid="B13">13</xref>]. The recent genome wide association study (GWAS) study in COPD by Pillai <italic>et al </italic>[<xref ref-type="bibr" rid="B31">31</xref>] didn't report association for <italic>MMP-12 </italic>in COPD even though there are SNPs in full linkage disequilibrium with rs2276109 and rs652438 on the illumina 550k platform used. However, this does not preclude the SNP's involvement in disease as they may have significance but not to genome wide level, access to the primary data would be of interest regarding this. Furthermore, in our population <italic>MMP-12 </italic>SNPs are associated with severe forms of COPD after haplotypic association, unlike the GWAS which is total COPD cases versus control population using single SNP association.</p><p>Although we noted a trend (p = 0.054) for association of SNP 14 (rs652438) with disease, our strict cut-off for significance indicates that it may require a much larger sample size to be confident of such an association. It is of note, however, that SNP 14 (rs652438) is a constituent of all the haplotypes found to be associated with severe/very severe disease, suggesting that it contributes to disease severity in COPD. It is also possible that this locus, or genetic variants in LD with rs652438, may affect susceptibility to COPD in the Chinese population. Whilst we did observe three haplotypes involving SNPs 13, 14 and 18 which were associated with severe/very severe disease (Table <xref ref-type="table" rid="T7">7</xref>), there was no significant association for a 2-SNP haplotype with SNPs 13 and 14 only.</p><p>SNP 18 (rs2276109) with the alleles A/G is a known functional variant where the A allele shows a higher affinity for the transcription factor activator protein-1 (AP-1), resulting in increased expression in gene reporter assays. In the current study, the A-A haplotype composed of SNP 18 (rs2276109) and SNP 14 (rs652438) is over-represented in the cases, suggesting that increased <italic>MMP</italic>-<italic>12 </italic>levels may contribute to COPD pathogenesis. This is consistent with observations of increased <italic>MMP</italic>-<italic>12 </italic>activity in the lungs of patients with COPD and with observations in a rodent model of disease where <italic>MMP-12 </italic>knock-outs are protected against smoking-induced emphysema.</p><p>A recent paper by McAloon <italic>et al </italic>[<xref ref-type="bibr" rid="B32">32</xref>], screened <italic>MMPs 1, 3 </italic>and <italic>12 </italic>relatively comprehensively in AATD with associations being found with gas transfer. This could allude to <italic>MMP - 12's </italic>role in parenchymal disease pathophysiology rather than airways disease, especially when considered with association in this study against severe forms of COPD and in previous studies with emphysema.</p></sec><sec><title>Conclusions</title><p>While this study provides suggestive evidence for a contribution of genetic variation in <italic>MMP-12 </italic>to disease severity in COPD, we do not find evidence for the involvement of <italic>MMP</italic>s- <italic>1 and 9 </italic>in COPD. This merits further investigation of <italic>MMP-12 </italic>associations in similar or larger cohorts.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>The authors IH, SC, JL, LD, COC and NK made substantial contribution to the conception and design of the study, and analysis and interpretation of the data. Whilst SJ, KM, TG, JR, RR, AM, SD, VK, WM, JS, PH, MM and SM made a substantial contribution to the collection of the resource and an intellectual contribution to the study design.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/11/7/prepub">http://www.biomedcentral.com/1471-2350/11/7/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>We thank Ann Hann (Bristol), Breda Callaghan and Gemma Hogan (Dublin), Joyce Barr (Edinburgh), Clara Kolster-Bijdevaate (Leiden) for assisting with recruitment; G. Catapano E. Fornai and C. Carli for clinical and technical assistance in Pisa. This work was supported by European Union 5<sup>th </sup>Framework Programme Grant QLG1-CT-200-01012 and the Medical Research Council UK. J. Lotya was supported by a grant from the Health Research Board (Ireland).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Mannino</surname><given-names>DM</given-names></name><name><surname>Buist</surname><given-names>AS</given-names></name><article-title>Global burden of COPD: risk factors, prevalence, and future trends</article-title><source>Lancet</source><year>2007</year><volume>370</volume><issue>9589</issue><fpage>765</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61380-4</pub-id><pub-id pub-id-type="pmid">17765526</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Devereux</surname><given-names>G</given-names></name><article-title>ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors</article-title><source>BMJ</source><year>2006</year><volume>332</volume><issue>7550</issue><fpage>1142</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1136/bmj.332.7550.1142</pub-id><pub-id pub-id-type="pmid">16690673</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Rennard</surname><given-names>SI</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><article-title>COPD: the dangerous underestimate of 15%</article-title><source>Lancet</source><year>2006</year><volume>367</volume><issue>9518</issue><fpage>1216</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)68516-4</pub-id><pub-id pub-id-type="pmid">16631861</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Laurell</surname><given-names>C-B</given-names></name><name><surname>Eriksson</surname><given-names>S</given-names></name><article-title>The Electrophoretic &#x003b1;;1-Globulin Pattern of Serum in &#x003b1;;1-Antitrypsin Deficiency</article-title><source>Scand J Clin Lab Invest</source><year>1963</year><volume>15</volume><issue>2</issue><fpage>132</fpage><lpage>140</lpage></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>D'Armiento</surname><given-names>J</given-names></name><name><surname>Dalal</surname><given-names>SS</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Berg</surname><given-names>RA</given-names></name><name><surname>Chada</surname><given-names>K</given-names></name><article-title>Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema</article-title><source>Cell</source><year>1992</year><volume>71</volume><issue>6</issue><fpage>955</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(92)90391-O</pub-id><pub-id pub-id-type="pmid">1458541</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Hautamaki</surname><given-names>RD</given-names></name><name><surname>Kobayashi</surname><given-names>DK</given-names></name><name><surname>Senior</surname><given-names>RM</given-names></name><name><surname>Shapiro</surname><given-names>SD</given-names></name><article-title>Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice</article-title><source>Science</source><year>1997</year><volume>277</volume><issue>5334</issue><fpage>2002</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1126/science.277.5334.2002</pub-id><pub-id pub-id-type="pmid">9302297</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Segura-Valdez</surname><given-names>L</given-names></name><name><surname>Pardo</surname><given-names>A</given-names></name><name><surname>Gaxiola</surname><given-names>M</given-names></name><name><surname>Uhal</surname><given-names>BD</given-names></name><name><surname>Becerril</surname><given-names>C</given-names></name><name><surname>Selman</surname><given-names>M</given-names></name><article-title>Upregulation of Gelatinases A and B, Collagenases 1 and 2, and Increased Parenchymal Cell Death in COPD</article-title><source>Chest</source><year>2000</year><volume>117</volume><issue>3</issue><fpage>684</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1378/chest.117.3.684</pub-id><pub-id pub-id-type="pmid">10712992</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Imai</surname><given-names>K</given-names></name><name><surname>Dalal</surname><given-names>SS</given-names></name><name><surname>Chen</surname><given-names>ES</given-names></name><name><surname>Downey</surname><given-names>R</given-names></name><name><surname>Schulman</surname><given-names>LL</given-names></name><name><surname>Ginsburg</surname><given-names>M</given-names></name><name><surname>D'Armiento</surname><given-names>J</given-names></name><article-title>Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>163</volume><issue>3 Pt 1</issue><fpage>786</fpage><lpage>791</lpage><pub-id pub-id-type="pmid">11254539</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Vernooy</surname><given-names>JH</given-names></name><name><surname>Lindeman</surname><given-names>JH</given-names></name><name><surname>Jacobs</surname><given-names>JA</given-names></name><name><surname>Hanemaaijer</surname><given-names>R</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><article-title>Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD</article-title><source>Chest</source><year>2004</year><volume>126</volume><issue>6</issue><fpage>1802</fpage><lpage>1810</lpage><pub-id pub-id-type="doi">10.1378/chest.126.6.1802</pub-id><pub-id pub-id-type="pmid">15596677</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Molet</surname><given-names>S</given-names></name><name><surname>Belleguic</surname><given-names>C</given-names></name><name><surname>Lena</surname><given-names>H</given-names></name><name><surname>Germain</surname><given-names>N</given-names></name><name><surname>Bertrand</surname><given-names>CP</given-names></name><name><surname>Shapiro</surname><given-names>SD</given-names></name><name><surname>Planquois</surname><given-names>JM</given-names></name><name><surname>Delaval</surname><given-names>P</given-names></name><name><surname>Lagente</surname><given-names>V</given-names></name><article-title>Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease</article-title><source>Inflamm Res</source><year>2005</year><volume>54</volume><issue>1</issue><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1007/s00011-004-1319-4</pub-id><pub-id pub-id-type="pmid">15723202</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Demedts</surname><given-names>IK</given-names></name><name><surname>Morel-Montero</surname><given-names>A</given-names></name><name><surname>Lebecque</surname><given-names>S</given-names></name><name><surname>Pacheco</surname><given-names>Y</given-names></name><name><surname>Cataldo</surname><given-names>D</given-names></name><name><surname>Joos</surname><given-names>GF</given-names></name><name><surname>Pauwels</surname><given-names>RA</given-names></name><name><surname>Brusselle</surname><given-names>GG</given-names></name><article-title>Elevated MMP-12 protein levels in induced sputum from patients with COPD</article-title><source>Thorax</source><year>2006</year><volume>61</volume><issue>3</issue><fpage>196</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1136/thx.2005.042432</pub-id><pub-id pub-id-type="pmid">16308335</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Babusyte</surname><given-names>A</given-names></name><name><surname>Stravinskaite</surname><given-names>K</given-names></name><name><surname>Jeroch</surname><given-names>J</given-names></name><name><surname>Lotvall</surname><given-names>J</given-names></name><name><surname>Sakalauskas</surname><given-names>R</given-names></name><name><surname>Sitkauskiene</surname><given-names>B</given-names></name><article-title>Patterns of airway inflammation and MMP-12 expression in smokers and ex-smokers with COPD</article-title><source>Respir Res</source><year>2007</year><volume>8</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-8-81</pub-id><pub-id pub-id-type="pmid">18001475</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Joos</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>JQ</given-names></name><name><surname>Shepherdson</surname><given-names>MB</given-names></name><name><surname>Connett</surname><given-names>JE</given-names></name><name><surname>Anthonisen</surname><given-names>NR</given-names></name><name><surname>Pare</surname><given-names>PD</given-names></name><name><surname>Sandford</surname><given-names>AJ</given-names></name><article-title>The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><issue>5</issue><fpage>569</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1093/hmg/11.5.569</pub-id><pub-id pub-id-type="pmid">11875051</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Minematsu</surname><given-names>N</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Tateno</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><article-title>Genetic Polymorphism in Matrix Metalloproteinase-9 and Pulmonary Emphysema</article-title><source>Biochemical and Biophysical Research Communications</source><year>2001</year><volume>289</volume><issue>1</issue><fpage>116</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2001.5936</pub-id><pub-id pub-id-type="pmid">11708786</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Wood</surname><given-names>AM</given-names></name><name><surname>Stockley</surname><given-names>RA</given-names></name><article-title>The genetics of chronic obstructive pulmonary disease</article-title><source>Respir Res</source><year>2006</year><volume>7</volume><fpage>130</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-7-130</pub-id><pub-id pub-id-type="pmid">17054776</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Chappell</surname><given-names>S</given-names></name><name><surname>Daly</surname><given-names>L</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Baranes</surname><given-names>TG</given-names></name><name><surname>Roca</surname><given-names>J</given-names></name><name><surname>Rabinovich</surname><given-names>R</given-names></name><name><surname>Millar</surname><given-names>A</given-names></name><name><surname>Donnelly</surname><given-names>SC</given-names></name><name><surname>Keatings</surname><given-names>V</given-names></name><name><surname>MacNee</surname><given-names>W</given-names></name><article-title>The SERPINE2 gene and chronic obstructive pulmonary disease</article-title><source>Am J Hum Genet</source><year>2006</year><volume>79</volume><issue>1</issue><fpage>184</fpage><lpage>186</lpage><comment>author reply 186-187</comment><pub-id pub-id-type="doi">10.1086/505268</pub-id><pub-id pub-id-type="pmid">16773582</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Chappell</surname><given-names>S</given-names></name><name><surname>Daly</surname><given-names>L</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Baranes</surname><given-names>TG</given-names></name><name><surname>Roca</surname><given-names>J</given-names></name><name><surname>Rabinovich</surname><given-names>R</given-names></name><name><surname>Millar</surname><given-names>A</given-names></name><name><surname>Donnelly</surname><given-names>SC</given-names></name><name><surname>Keatings</surname><given-names>V</given-names></name><name><surname>Macnee</surname><given-names>W</given-names></name><article-title>Variation in the tumour necrosis factor gene is not associated with susceptibility to COPD</article-title><source>Eur Respir J</source><year>2007</year><volume>30</volume><issue>4</issue><fpage>810</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1183/09031936.00057107</pub-id><pub-id pub-id-type="pmid">17906092</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Chappell</surname><given-names>S</given-names></name><name><surname>Daly</surname><given-names>L</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Guetta-Baranes</surname><given-names>T</given-names></name><name><surname>Roca</surname><given-names>J</given-names></name><name><surname>Rabinovich</surname><given-names>R</given-names></name><name><surname>Lotya</surname><given-names>J</given-names></name><name><surname>Millar</surname><given-names>AB</given-names></name><name><surname>Donnelly</surname><given-names>SC</given-names></name><name><surname>Keatings</surname><given-names>V</given-names></name><article-title>Genetic variants of microsomal epoxide hydrolase and glutamate-cysteine ligase in COPD</article-title><source>Eur Respir J</source><year>2008</year><volume>32</volume><issue>4</issue><fpage>931</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1183/09031936.00065308</pub-id><pub-id pub-id-type="pmid">18614560</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Chappell</surname><given-names>S</given-names></name><name><surname>Daly</surname><given-names>L</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Guetta Baranes</surname><given-names>T</given-names></name><name><surname>Roca</surname><given-names>J</given-names></name><name><surname>Rabinovich</surname><given-names>R</given-names></name><name><surname>Millar</surname><given-names>A</given-names></name><name><surname>Donnelly</surname><given-names>SC</given-names></name><name><surname>Keatings</surname><given-names>V</given-names></name><name><surname>MacNee</surname><given-names>W</given-names></name><article-title>Cryptic haplotypes of SERPINA1 confer susceptibility to chronic obstructive pulmonary disease</article-title><source>Hum Mutat</source><year>2006</year><volume>27</volume><issue>1</issue><fpage>103</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1002/humu.20275</pub-id><pub-id pub-id-type="pmid">16278826</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="other"><article-title>Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD</article-title><source>The Global Initiative for Chronic Obstructive Lung Disease</source><year>2008</year></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><article-title>Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls</article-title><source>Nature</source><year>2007</year><volume>447</volume><issue>7145</issue><fpage>661</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/nature05911</pub-id><pub-id pub-id-type="pmid">17554300</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Yuan</surname><given-names>H-Y</given-names></name><name><surname>Chiou</surname><given-names>J-J</given-names></name><name><surname>Tseng</surname><given-names>W-H</given-names></name><name><surname>Liu</surname><given-names>C-H</given-names></name><name><surname>Liu</surname><given-names>C-K</given-names></name><name><surname>Lin</surname><given-names>Y-J</given-names></name><name><surname>Wang</surname><given-names>H-H</given-names></name><name><surname>Yao</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Y-T</given-names></name><name><surname>Hsu</surname><given-names>C-N</given-names></name><article-title>FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization</article-title><source>Nucl Acids Res</source><year>2006</year><volume>34</volume><issue>suppl_2</issue><fpage>W635</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl236</pub-id><pub-id pub-id-type="pmid">16845089</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="book"><collab>Institute S</collab><source>SAS/Genetics user's guide</source><year>2000</year><publisher-name>Cary, NC: SAS Institute</publisher-name></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><issue>2</issue><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bth457</pub-id><pub-id pub-id-type="pmid">15297300</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Tesfaigzi</surname><given-names>Y</given-names></name><name><surname>Myers</surname><given-names>OB</given-names></name><name><surname>Stidley</surname><given-names>CA</given-names></name><name><surname>Schwalm</surname><given-names>K</given-names></name><name><surname>Picchi</surname><given-names>M</given-names></name><name><surname>Crowell</surname><given-names>RE</given-names></name><name><surname>Gilliland</surname><given-names>FD</given-names></name><name><surname>Belinsky</surname><given-names>SA</given-names></name><article-title>Genotypes in matrix metalloproteinase 9 are a risk factor for COPD</article-title><source>Int J Chron Obstruct Pulmon Dis</source><year>2006</year><volume>1</volume><issue>3</issue><fpage>267</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">18046864</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Herold</surname><given-names>C</given-names></name><name><surname>Becker</surname><given-names>T</given-names></name><article-title>Genetic association analysis with FAMHAP: a major program update</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><issue>1</issue><fpage>134</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btn581</pub-id><pub-id pub-id-type="pmid">19015131</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Becker</surname><given-names>T</given-names></name><name><surname>Knapp</surname><given-names>M</given-names></name><article-title>A powerful strategy to account for multiple testing in the context of haplotype analysis</article-title><source>Am J Hum Genet</source><year>2004</year><volume>75</volume><issue>4</issue><fpage>561</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1086/424390</pub-id><pub-id pub-id-type="pmid">15290652</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Kall</surname><given-names>L</given-names></name><name><surname>Storey</surname><given-names>JD</given-names></name><name><surname>MacCoss</surname><given-names>MJ</given-names></name><name><surname>Noble</surname><given-names>WS</given-names></name><article-title>Posterior error probabilities and false discovery rates: two sides of the same coin</article-title><source>J Proteome Res</source><year>2008</year><volume>7</volume><issue>1</issue><fpage>40</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1021/pr700739d</pub-id><pub-id pub-id-type="pmid">18052118</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="other"><article-title>The R Project for Statistical Computing</article-title><ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/index.html">http://www.r-project.org/index.html</ext-link></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>RB</given-names></name><name><surname>He</surname><given-names>QY</given-names></name><name><surname>Yang</surname><given-names>RH</given-names></name><name><surname>Lu</surname><given-names>BB</given-names></name><name><surname>YJ</surname><given-names>L</given-names></name><article-title>Study on matrix metalloproteinase 1, 9, 12 polymorphisms and susceptibility to chronic obstructive pulmonary disease among Han nationality in northern China</article-title><source>Zhonghua Liu Xing Bing Xue Za Zhi</source><year>2005</year><volume>26</volume><issue>11</issue><fpage>907</fpage><lpage>910</lpage><pub-id pub-id-type="pmid">16676616</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Pillai</surname><given-names>SG</given-names></name><name><surname>Ge</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Shianna</surname><given-names>KV</given-names></name><name><surname>Need</surname><given-names>AC</given-names></name><name><surname>Feng</surname><given-names>S</given-names></name><name><surname>Hersh</surname><given-names>CP</given-names></name><name><surname>Bakke</surname><given-names>P</given-names></name><name><surname>Gulsvik</surname><given-names>A</given-names></name><article-title>A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci</article-title><source>PLoS Genet</source><year>2009</year><volume>5</volume><issue>3</issue><fpage>e1000421</fpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1000421</pub-id><pub-id pub-id-type="pmid">19300482</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>McAloon</surname><given-names>CJ</given-names></name><name><surname>Wood</surname><given-names>AM</given-names></name><name><surname>Gough</surname><given-names>SC</given-names></name><name><surname>Stockley</surname><given-names>RA</given-names></name><article-title>Matrix metalloprotease polymorphisms are associated with gas transfer in alpha 1 antitrypsin deficiency</article-title><source>Ther Adv Respir Dis</source><year>2009</year><volume>3</volume><issue>1</issue><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1177/1753465809102263</pub-id><pub-id pub-id-type="pmid">19293200</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>SG</given-names></name><name><surname>Wan</surname><given-names>HY</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Deng</surname><given-names>WW</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><article-title>Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China</article-title><source>Chin Med J (Engl)</source><year>2004</year><volume>117</volume><issue>10</issue><fpage>1481</fpage><lpage>1484</lpage><pub-id pub-id-type="pmid">15498369</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Ito</surname><given-names>I</given-names></name><name><surname>Nagai</surname><given-names>S</given-names></name><name><surname>Handa</surname><given-names>T</given-names></name><name><surname>Muro</surname><given-names>S</given-names></name><name><surname>Hirai</surname><given-names>T</given-names></name><name><surname>Tsukino</surname><given-names>M</given-names></name><name><surname>Mishima</surname><given-names>M</given-names></name><article-title>Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema</article-title><source>Am J Respir Crit Care Med</source><year>2005</year><volume>172</volume><issue>11</issue><fpage>1378</fpage><lpage>1382</lpage><pub-id pub-id-type="doi">10.1164/rccm.200506-953OC</pub-id><pub-id pub-id-type="pmid">16126934</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Hersh</surname><given-names>CP</given-names></name><name><surname>DeMeo</surname><given-names>DL</given-names></name><name><surname>Lazarus</surname><given-names>R</given-names></name><name><surname>Celedon</surname><given-names>JC</given-names></name><name><surname>Raby</surname><given-names>BA</given-names></name><name><surname>Benditt</surname><given-names>JO</given-names></name><name><surname>Criner</surname><given-names>G</given-names></name><name><surname>Make</surname><given-names>B</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name><name><surname>Scanlon</surname><given-names>PD</given-names></name><article-title>Genetic Association Analysis of Functional Impairment in Chronic Obstructive Pulmonary Disease</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>173</volume><issue>9</issue><fpage>977</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1164/rccm.200509-1452OC</pub-id><pub-id pub-id-type="pmid">16456143</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Schirmer</surname><given-names>H</given-names></name><name><surname>Basso da Silva</surname><given-names>L</given-names></name><name><surname>Teixeira</surname><given-names>PJ</given-names></name><name><surname>Moreira</surname><given-names>JS</given-names></name><name><surname>Moreira</surname><given-names>AL</given-names></name><name><surname>Simon</surname><given-names>D</given-names></name><article-title>Matrix metalloproteinase gene polymorphisms: lack of association with chronic obstructive pulmonary disease in a Brazilian population</article-title><source>Genet Mol Res</source><year>2009</year><volume>8</volume><issue>3</issue><fpage>1028</fpage><lpage>1034</lpage><pub-id pub-id-type="doi">10.4238/vol8-3gmr596</pub-id><pub-id pub-id-type="pmid">19731200</pub-id></mixed-citation></ref></ref-list></back></article>